You're signed outSign in or to get full access.
MPM Asset Management LLC
MPM Asset Management LLC, now operating under the name MPM BioImpact, is a Boston-based investment adviser and asset manager specializing in life sciences and biotechnology investments. The firm was founded in 1997 and manages venture capital and public equity strategies focused on the biotech and healthcare sectors. MPM serves institutional investors, academic endowments, and other sophisticated entities with a team of approximately 50 professionals, including scientists, clinicians, and investment specialists. The firm is deeply involved in company creation and growth, often leading investments in early-stage and emerging companies developing transformative therapeutics.
Investment Strategy
MPM focuses on investing in and building innovative biotechnology companies, particularly those developing breakthrough therapies in areas of high unmet medical need. The firm takes an active approach to company creation, leveraging scientific, clinical, and operational expertise to guide portfolio companies from early discovery through clinical development and potential commercialization. MPM often partners with leading academic institutions and pharma, aiming to create value through strategic guidance, operational support, and growth capital. The firm's investment philosophy emphasizes significant scientific innovation and attractive risk-adjusted returns across private and public markets within life sciences.
Latest 13F Filing Activity
MPM Asset Management LLC filed their most recent 13F report on Jun 30, 2025 disclosing 5 equity positions with a total 13F market value of $43M. The fund increased holdings in Werewolf Therapeutics, Inc., Repare Therapeutics, Inc., Adaptimmune Therapeutics PLC among other positions. MPM Asset Management LLC reduced exposure to Entrada Therapeutics, Inc., Dyne Therapeutics, Inc., Adaptimmune Therapeutics PLC among others.
Top Holdings
Equity Positions (5)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
T TRDA | Entrada Therapeutics, Inc. | 67.92% | $29.4M | 4,381,062 | $17.12 | $6.72 | -$10.2M |
D DYN | Dyne Therapeutics, Inc. | 14.99% | $6.5M | 682,376 | $20.19 | $9.52 | -$641.4K |
H HOWL | Werewolf Therapeutics, Inc. | 10.84% | $4.7M | 4,309,860 | $17.34 | $1.09 | +$508.6K |
R RPTX | Repare Therapeutics, Inc. | 3.60% | $1.6M | 1,121,318 | $31.02 | $1.39 | +$453.0K |
A ADAP | Adaptimmune Therapeutics plc | 2.66% | $1.2M | 4,809,677 | $0.93 | $0.24 | +$101.7K |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more